Neumora Therapeutics Inc NMRA.OQ NMRA.O is expected to show no change in quarterly revenue when it reports results on March 30 for the period ending December 31 2025
LSEG's mean analyst estimate for Neumora Therapeutics Inc is for a loss of 33 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Neumora Therapeutics Inc is $7.50, about 201.2% above its last closing price of $2.49
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.32 | -0.33 | -0.32 | Beat | 4.1 |
Jun. 30 2025 | -0.36 | -0.37 | -0.33 | Beat | 10.4 |
Mar. 31 2025 | -0.35 | -0.37 | -0.42 | Missed | -12.2 |
Dec. 31 2024 | -0.46 | -0.45 | -0.37 | Beat | 17.1 |
Sep. 30 2024 | -0.38 | -0.39 | -0.45 | Missed | -15.4 |
Jun. 30 2024 | -0.38 | -0.37 | -0.37 | Met | 0.4 |
Mar. 31 2024 | -0.34 | -0.34 | -0.34 | Met | 0.6 |
Dec. 31 2023 | -0.73 | -0.55 | -0.71 | Missed | -29.1 |
This summary was machine generated March 27 at 13:13 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)